Randomized, placebo-controlled, phase II trial of EGFR and COX-2 inhibition in advanced non-small cell lung cancer

被引：0
|
作者：
Reckamp, K. L.
Koczywas, M.
Cristea, M. C.
Dowell, J.
Gardner, B.
Milne, G.
Rad, S. Fouladi
Figlin, R. A.
Elashoff, R.
Dubinett, S. M.
机构：
[1] City Hope Natl Med Ctr, Duarte, CA USA
[2] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA
[3] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA
[4] Vanderbilt Univ, Nashville, TN 37235 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.tps337
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS337
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Phase III randomized, placebo controlled trial of COX-2 inhibition in addition to standard chemotherapy for advanced non-small cell lung cancer (NSCLC):CALGB 30801 (Alliance)
    Edelman, Martin J.
    Wang, Xiaofei
    Hodgson, Lydia
    Cheney, Richard T.
    Baggstrom, Maria
    Sachdev, Thomas
    Gajra, Ajeet
    Bertino, Erin
    Reckamp, Karen
    Molina, Julian
    Schiller, Joan
    Mitchell-Richards, Kisha
    Friedman, Paula
    Ritter, Jon
    Vokes, Everett
    CANCER RESEARCH, 2014, 74 (19)
  • [2] Targeted COX-2 and EGFR TK inhibition in advanced non-small cell lung cancer.
    Reckamp, K. L.
    Czernin, J.
    Weber, W. A.
    Dubinett, S. M.
    Figlin, R. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 408S - 408S
  • [3] Economic Analysis: Randomized Placebo-Controlled Clinical Trial of Erlotinib in Advanced Non-Small Cell Lung Cancer
    Bradbury, Penelope A.
    Tu, Dongsheng
    Seymour, Lesley
    Isogai, Pierre K.
    Zhu, Liting
    Ng, Raymond
    Mittmann, Nicole
    Tsao, Ming-Sound
    Evans, William K.
    Shepherd, Frances A.
    Leighl, Natasha B.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2010, 102 (05): : 298 - 306
  • [4] Randomized, Placebo-Controlled, Phase II Study of Veliparib in Combination with Carboplatin and Paclitaxel for Advanced/Metastatic Non-Small Cell Lung Cancer
    Ramalingam, Suresh S.
    Blais, Normand
    Mazieres, Julien
    Reck, Martin
    Jones, C. Michael
    Juhasz, Erzsebet
    Urban, Laszlo
    Orlov, Sergey
    Barlesi, Fabrice
    Kio, Ebenezer
    Keiholz, Ulrich
    Qin, Qin
    Qian, Jiang
    Nickner, Caroline
    Dziubinski, Juliann
    Xiong, Hao
    Ansell, Peter
    McKee, Mark
    Giranda, Vincent
    Gorbunova, Vera
    CLINICAL CANCER RESEARCH, 2017, 23 (08) : 1937 - 1944
  • [5] Pharmacogenetic Analysis of BR.21, a Placebo-Controlled Randomized Phase III Clinical Trial of Erlotinib in Advanced Non-small Cell Lung Cancer
    Liu, Geoffrey
    Cheng, D.
    Ding, K.
    Le Maitre, A.
    Liu, N.
    Patel, D.
    Chen, Z.
    Seymour, L.
    Shepherd, F. A.
    Tsao, M. S.
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (02) : 316 - 322
  • [6] Urinary PGE-M as a Biomarker for COX-2 Inhibition in Advanced Non-small Cell Lung Cancer
    Reckamp, K. L.
    Koczywas, M.
    Cristea, M.
    Dowell, J. E.
    Gardner, B.
    Milne, G.
    Rad, S. Fouladi
    Figlin, R. A.
    Elashoff, R.
    Dubinett, S. M.
    JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (12) : S546 - S546
  • [7] Phase II/III clinical trial of randomized, double-blind, placebo-controlled combined with recombinant human endostatin in treatment of advanced non-small cell lung cancer
    Xu Liyan
    Shi He Heling
    Liu Zhe
    Zhu Yunzhong
    Li Baolan
    Zhang Shucai
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S354 - S354
  • [8] The effect of COX-2 inhibition on molecular responses of rectal cancer to preoperative chemoradiation in a phase II randomized, double blind, placebo-controlled clinical trial
    Debucquoy, A
    Goethals, L
    McBride, WH
    Haustermans, K
    RADIOTHERAPY AND ONCOLOGY, 2006, 78 : S53 - S53
  • [9] A randomized phase II trial of erlotinib or erlotinib and bevacizumab in patients with advanced EGFR mutant non-small cell lung cancer (NSCLC)
    Stinchcombe, T. E.
    Janne, P. A.
    Wang, X.
    Bertino, E. M.
    Weiss, J. M.
    Bazhenova, L.
    Gu, L.
    Lau, C. J.
    Paweletz, C. P.
    Jaslowski, A. J.
    Gerstner, G. J.
    Baggstrom, M. Q.
    Graziano, S. L.
    Beardenlii, J.
    Vokes, E. E.
    ANNALS OF ONCOLOGY, 2018, 29 : 522 - 522
  • [10] A phase III randomized placebo controlled NCCTG trial of carboxyaminoimidazole (CAI) in patients with advanced non-small cell lung cancer (NSCLC).
    Johnson, EA
    Marks, RS
    Mandrekar, S
    Hillman, S
    Mailliard, J
    Dentchev, T
    Reuter, N
    Jett, J
    Perez, EA
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 634S - 634S
12345